Condition
Optic Nerve Glioma
Total Trials
6
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 1 (2)
P 2 (1)
P 3 (1)
Trial Status
Completed3
Withdrawn2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04648462Recruiting
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
NCT01837862Phase 1Completed
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
NCT03326388Phase 1Completed
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
NCT02839720Phase 2Completed
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
NCT01260103Phase 3WithdrawnPrimary
Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
NCT02976441Early Phase 1Withdrawn
Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
Showing all 6 trials